Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Group Incompatibility | 3 | 2016 | 11 | 1.100 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 20 | 1.100 |
Why?
|
| Erythrocytes | 3 | 2017 | 45 | 0.930 |
Why?
|
| Kidney Transplantation | 3 | 2016 | 518 | 0.920 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2020 | 8 | 0.740 |
Why?
|
| Blood Preservation | 2 | 2017 | 9 | 0.620 |
Why?
|
| Medical Waste | 1 | 2017 | 2 | 0.600 |
Why?
|
| Cold Temperature | 1 | 2017 | 49 | 0.590 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 4 | 0.510 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 9 | 0.510 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 10 | 0.500 |
Why?
|
| Erythrocyte Transfusion | 5 | 2020 | 33 | 0.500 |
Why?
|
| Autoantibodies | 1 | 2015 | 62 | 0.490 |
Why?
|
| HLA Antigens | 1 | 2014 | 40 | 0.470 |
Why?
|
| Cryopreservation | 2 | 2010 | 55 | 0.420 |
Why?
|
| Hypersensitivity | 2 | 2008 | 27 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2010 | 95 | 0.370 |
Why?
|
| Fever | 2 | 2008 | 63 | 0.370 |
Why?
|
| Troponin | 2 | 2020 | 99 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 541 | 0.340 |
Why?
|
| Immunization | 1 | 2009 | 35 | 0.330 |
Why?
|
| Autoimmunity | 1 | 2009 | 34 | 0.330 |
Why?
|
| Diphenhydramine | 1 | 2008 | 3 | 0.330 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 9 | 0.320 |
Why?
|
| Premedication | 1 | 2008 | 14 | 0.320 |
Why?
|
| Acetaminophen | 1 | 2008 | 20 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 77 | 0.300 |
Why?
|
| Humans | 17 | 2020 | 32297 | 0.280 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 7 | 0.270 |
Why?
|
| Isoantibodies | 1 | 2005 | 12 | 0.260 |
Why?
|
| Adult | 8 | 2020 | 9467 | 0.260 |
Why?
|
| Blood Donors | 2 | 2003 | 13 | 0.240 |
Why?
|
| von Willebrand Diseases | 1 | 2003 | 1 | 0.230 |
Why?
|
| Blood Component Removal | 1 | 2003 | 2 | 0.230 |
Why?
|
| Fibrinogen | 1 | 2003 | 43 | 0.230 |
Why?
|
| Factor VIII | 1 | 2003 | 22 | 0.230 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 225 | 0.230 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 17 | 0.230 |
Why?
|
| Male | 9 | 2020 | 19488 | 0.210 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2016 | 9 | 0.210 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 18 | 0.180 |
Why?
|
| Ambulances | 1 | 2020 | 14 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2020 | 26 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 165 | 0.150 |
Why?
|
| Blood Banks | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hospitals | 1 | 2017 | 99 | 0.140 |
Why?
|
| Platelet Transfusion | 2 | 2008 | 16 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 469 | 0.130 |
Why?
|
| Time Factors | 5 | 2020 | 2181 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2008 | 101 | 0.130 |
Why?
|
| Middle Aged | 6 | 2020 | 11949 | 0.130 |
Why?
|
| Cryoglobulins | 1 | 2015 | 5 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2016 | 199 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2015 | 52 | 0.120 |
Why?
|
| Female | 7 | 2020 | 20126 | 0.120 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 26 | 0.120 |
Why?
|
| Brain Death | 1 | 2014 | 30 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 121 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2014 | 3358 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2014 | 239 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1133 | 0.100 |
Why?
|
| Aged | 3 | 2020 | 10398 | 0.100 |
Why?
|
| Iron Overload | 1 | 2009 | 38 | 0.090 |
Why?
|
| Leukemia | 1 | 2009 | 40 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 2274 | 0.080 |
Why?
|
| Iron | 1 | 2009 | 117 | 0.080 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2008 | 2 | 0.080 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 10 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2009 | 75 | 0.080 |
Why?
|
| Plasma | 1 | 2008 | 14 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 210 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 279 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 301 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2008 | 550 | 0.070 |
Why?
|
| Leukapheresis | 2 | 2004 | 2 | 0.070 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2005 | 2 | 0.070 |
Why?
|
| Glycosuria, Renal | 1 | 2005 | 3 | 0.070 |
Why?
|
| Hemolysis | 1 | 2005 | 13 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 267 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2005 | 58 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 151 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2003 | 681 | 0.060 |
Why?
|
| Circumcision, Male | 1 | 2003 | 4 | 0.060 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 5 | 0.060 |
Why?
|
| Blood-Borne Pathogens | 1 | 2003 | 7 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 3876 | 0.060 |
Why?
|
| Fathers | 1 | 2003 | 12 | 0.060 |
Why?
|
| Plasma Exchange | 1 | 2003 | 14 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2003 | 22 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2003 | 52 | 0.060 |
Why?
|
| Stem Cell Factor | 1 | 2001 | 13 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 24 | 0.050 |
Why?
|
| Neoplasms | 1 | 2008 | 695 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 57 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 100 | 0.050 |
Why?
|
| Cell Separation | 1 | 2001 | 94 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 45 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2001 | 332 | 0.050 |
Why?
|
| Adolescent | 1 | 2008 | 3571 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 926 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 600 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2009 | 491 | 0.040 |
Why?
|
| Mice | 1 | 2001 | 2524 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1447 | 0.030 |
Why?
|
| Cell Division | 2 | 2001 | 98 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 5 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2009 | 24 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2008 | 94 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2008 | 3514 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 696 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 313 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 1523 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2001 | 13 | 0.010 |
Why?
|
| E-Selectin | 1 | 2001 | 20 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 26 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 56 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 95 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 154 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1207 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 773 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 7694 | 0.010 |
Why?
|